Gilead Reports Results of Selonsertib in P-III STELLAR 3 Study for Bridging Fibrosis (F3) due to NASH

 Gilead Reports Results of Selonsertib in P-III STELLAR 3 Study for Bridging Fibrosis (F3) due to NASH

Gilead Reports Results of Selonsertib in P-III STELLAR 3 Study for Bridging Fibrosis (F3) due to NASH

Shots:

  • The P-III STELLAR 3 study involves assessing of Selonsertib (18mg, 6mg) vs PBO in 802 patients with F3/bridging fibrosis due to NASH in adults aged 18 to 70yrs for 240wks.
  • The P-III study results: @48 wks. did not meet its 1EPs; ≥ 1-stage improvement in fibrosis without NASH worsening (9.3%, 12.1% vs 13.2%); well tolerated
  • Selonsertib (qd, PO) is a signal-regulating kinase 1 (ASK1) inhibitor and is evaluated in P-II ATLAS study in combination with selonsertib, cilofexor and firsocostat in patients with advanced fibrosis due to NASH with its expected results in H2’19. In H1’19, P-III study assessing Selonsertib in patients with F4 fibrosis has also failed in meeting its 1EPs

Click here to read full press release/ article | Ref: Gilead | Image: Glassdoor

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post